MILWAUKEE, Nov. 16, 2023 /PRNewswire/ — Ademi LLP is investigating Graphite Bio (NASDAQ: GRPH) for possible breaches of fiduciary duty and other violations of law in its transaction with LENZ Therapeutics.
Click here to learn how to join the https://www.ademilaw.com/case/graphite-bio-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.
Graphite Bio stockholders are expected to own approximately 35% of the combined company and LENZ Therapeutics stockholders are expected to own approximately 65% of the combined company upon the closing of the merger. The transaction agreement unreasonably limits competing transactions for Graphite Bio by imposing a significant penalty if Graphite Bio accepts a competing bid. Graphite Bio insiders will receive substantial benefits as part of change of control arrangements.
We are investigating the conduct of Graphite Bio’s board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.
If you own Graphite Bio common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or https://www.ademilaw.com/case/graphite-bio-inc.
We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Contacts
Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001
SOURCE Ademi LLP
